Pabrinex shortage and guidance on alternatives
Pabrinex IV will be out of stock from July/ August 2024 until September 2025, due to supply issues relating to manufacturing regulations issued by the EU. Pabrinex IM will be permanently discontinued from December 2024. Pabrinex is only used in the UK, with thiamine IV/ IM being routinely used globally.
It is important to note if a Patient Group Direction (PGD) is being used (often used in community setting), only licensed products can be used in this setting. Therefore IM Pabrinex should be conserved for this purpose.
The following has been published online by the DHSC Specialist Pharmacy Service.
Joanna Henry, Gastroenterology Directorate Pharmacist, Liverpool University Hospitals NHS Trust
Sital Shah, Chair British Hepatology Pharmacy Group , Consultant Pharmacist, King’s College Hospital, London
Applications open for BSG CSSC Clinical Guidelines Lead
Applications are now open for the role of BSG CSSC Clinical Guidelines Lead from October 2025.
BSG Travelling Fellowship – AASLD and visit to the National Institute of Health in Baltimore
This fellowship aims to offer an opportunity for a trainee who has a strong interest in Hepatology to attend AASLD’s Liver Meeting in Washington DC, USA in November 2025 to see the latest research and clinical updates in Hepatology.
Perceptions and impact of Alcohol Minimum Unit Pricing
Dr Ewan Forrest, BSG Alcohol Lead, and Dr Coral Hollywood, BSG VP Hepatology, discuss the perceptions and impact of Minimum Unit Pricing of alcohol in Scotland, and the benefits of introducing a similar approach in England.